Regulatory approval delays
Deliveries in several markets cannot begin until local approvals are obtained.
- Scope
- Asia expansion and Japan
- Materiality
- high
Braincool
BrainCool is a Swedish medical device company focused on patient temperature management systems used in acute care and other hospital settings. Its product platform includes BrainCool/IQool, RhinoChill, and Cooral systems, each supported by related consumables and managed through separate subsidiaries.
| % | |
|---|---|
| Cooling systems | 55% Reusable medical cooling devices sold for specific acute-care and oncology indications. |
| Consumables | 35% Single-use cooling pads and related items used with installed systems. |
| Distribution and system sales | 10% Partner-led sales of systems through distributors such as ZOLL in multiple markets. |
BrainCool sells primarily to hospitals, emergency care providers, and healthcare systems that treat stroke, cardiac...
- Hospital acute-care departmentsprimary
Buy BrainCool/IQool systems for in-hospital temperature management in neurological and cardiac indications.
- Emergency medical servicessecondary
Use RhinoChill-type solutions for rapid cooling in pre-hospital or emergency settings.
- Oncology and infusion clinicssecondary
Use Cooral-related cooling solutions to reduce side effects of chemotherapy.
- Distribution partnersprimary
Purchase and market systems in defined territories, expanding reach and regulatory coverage.
BrainCool is headquartered in Sweden and sells through a distributor-led model across Europe, the U.S...
- •Sweden is the corporate and development base
- •U.S. is a key commercial market through the ZOLL agreement
- •Germany, Switzerland, and Austria are covered by distributor channels
- •Asia expansion includes Thailand, Malaysia, Japan, and other markets
- •Regulatory approvals determine when deliveries can begin in each country
BrainCool’s strategy is to expand its installed base through distributor partnerships while increasing recurring...
01
Expand distributor-led commercializationshort-term
Channel partners extend market reach without building a large direct sales force.
02
Increase installed base and consumables attach ratemedium-term
Each system sold can generate recurring demand for pads and other single-use items.
03
Advance clinical and regulatory validationmedium-term
Medical adoption depends on evidence generation and country-by-country approvals.
BrainCool faces regulatory, clinical, and commercialization risk because each market and indication requires evidence,...
Clinical adoption and evidence risk
Hospital buyers rely on clinical studies and proven outcomes before broad adoption.
- Scope
- All product lines
- Materiality
- high
Distributor concentration
A significant portion of commercialization depends on partners such as ZOLL.
- Scope
- U.S. and selected international markets
- Materiality
- high
Supplier and manufacturing dependence
Production is subcontracted, so quality, lead times, and supply continuity matter.
- Scope
- All products
- Materiality
- medium
Capitalized development costs and patents
Intangible assets and operating profit
Revenue recognition on system and consumable sales
Quarterly revenue mix and gross margin
Seasonality
Reported quarterly sales and margins
Deferred tax assets on loss carryforwards
Balance sheet and tax expense
: 11/08/2026